Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Brain Dev. 2017 Feb 24;39(6):483–492. doi: 10.1016/j.braindev.2017.01.012

Figure 1.

Figure 1

Candidate genes association with the differential effect of sertraline treatment on CGI-I. A) In the case of 2C19, a higher percent of the intermediate and poor metabolizers were very much improved in the active arm but not in the placebo; B) MAOA genotypes 2/2, 3/3, 3/4 and 3.5/4 showed higher percent of very much improved since the initiation of treatment in the active arm compared to placebo; C) Subjects with the BDNF val/val genotype in the active arm had higher rate of very much improved compared to placebo.